X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

The Senate’s latest price setting proposal will undermine: Patient access to medicines

By Nicole Longo  |    July 26, 2022
Members of Congress continue to push a misguided drug pricing proposal under the guise of negotiation as part of the reconciliation package. This proposal is nothing short of government price setting...   Read More

Part D 101: Three charts show how the Medicare Part D program could be improved to work better for seniors and people with disabilities

By Gabby Migliara  |    April 27, 2022
In yesterday’s post, we learned how Medicare Part D works for seniors and people with disabilities. Unfortunately, Part D beneficiaries are increasingly facing higher out-of-pocket costs for the...   Read More

Part D 101: Three charts show how the program provides comprehensive prescription drug coverage

By Gabby Migliara  |    April 26, 2022
Medicare Part D provides prescription drug coverage for our nation’s seniors and Americans with disabilities. These beneficiaries can opt to enroll in Part D and pick from a variety of plans offered....   Read More

It’s a new year, but sadly Congress is still pursuing flawed price setting policies

By Nicole Longo  |    January 25, 2022
As we kick off 2022, Congress has a number of priorities they are aiming to tackle, including the Build Back Better Act (BBBA). Unfortunately, the bill includes policies that would take the...   Read More

Post-approval research save lives. Why is Congress trying disincentivize it?

By Andrew Powaleny  |    December 17, 2021
While some in Congress continue to claim the latest drug pricing plan in Washington is “negotiation,” that is far from the truth. The reality is that the current plan gives the government a new...   Read More

A price control by any other name would still put patients at risk and threaten innovation

By Nicole Longo  |    December 9, 2021
Some policymakers in DC are laser focused on giving the government the power to “negotiate” in Medicare. What they aren’t saying is that this isn’t negotiation at all. They essentially just want the...   Read More

New data show insurers and PBMs increase barriers to care

By Katie Koziara  |    December 2, 2021
New data show insurers and middlemen known as pharmacy benefit managers (PBMs) are making it harder for patients to get the medicines they need.   Read More

Making medicines more affordable: Modernizing Medicare

By Emilie Signora  |    November 11, 2021
Common-sense reforms can help ensure everyone benefits from America’s engine of innovation and receives the care they need and deserve. In this series, we’re taking a closer look at PhRMA’s advocacy...   Read More

ICYMI: New study confirms policies like H.R. 3 could significantly reduce drug development

By Gabby Migliara  |    October 18, 2021
A new study from economists at the University of Chicago examined the impact that government price-setting policies for medicines, like those in H.R. 3, could have if implemented. The economists...   Read More

America’s biopharmaceutical companies to Congress: Government “negotiation” is the wrong approach

By Stephen J. Ubl  |    September 15, 2021
Today, PhRMA member companies made public an open letter to Capitol Hill to encourage Congress to abandon old partisan ideas on drug pricing and instead pursue policies that actually address what...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates